Transcranial magnetic stimulation for schizophrenia: potential and risks

Peggy Bosch¹,², Sujung Yeo³, Heike Staudte¹, Pia Barisch¹,⁴, Sabina Lim⁵, Maurits van den Noort⁵,⁶

²Centre for Cognition, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, 6500 GL Nijmegen, Gelderland, The Netherlands.
³College of Korean Medicine, Sang Ji University, Wonju 26339, South Korea.
⁴Institute of Experimental Psychology, Heinrich Heine University, 40225 Düsseldorf, Germany.
⁵Research Group of Pain and Neuroscience, Kyung Hee University, Seoul 130-701, South Korea.

How to cite this article: Bosch P, Yeo S, Staudte H, Barisch P, Lim S, van den Noort M. Transcranial magnetic stimulation for schizophrenia: potential and risks. Neuroimmunol Neuroinflammation 2017;4:258-9.

Article history: Received: 9 Sep 2017      Accepted: 11 Sep 2017      Published: 6 Dec 2017

Recently, transcranial magnetic stimulation (TMS) has increasingly been used to investigate the neurobiology of schizophrenia. In those studies, researchers applied TMS in combination with motor evoked potentials (TMS/MEPs) and high density electroencephalograms (TMS/hd-EEG)¹. The studies revealed significant impairments in cortical excitability, inhibition, and oscillatory activity, which are more prominent in the frontal brain areas, in patients suffering from schizophrenia compared to healthy controls¹. Future TMS studies may help explain the underlying neurobiology of schizophrenia, and TMS may help monitor and perhaps further optimize the effectiveness of treatment interventions in patients with this disease. However, despite the potential of using TMS in the investigation of the underlying neurobiology of schizophrenia, three critical notes are essential.

First, so far, TMS studies on schizophrenia have been neither robust, consistent, nor standardized enough and have had high risks of publication bias, as was recently concluded in a large systematic review of forty-one trials by Dougall and colleagues². Studies differ in numerous variables, for example, the stimulation intensity or length, the areas of the brain that are stimulated, and the design of the same TMS condition. Those variables could have great impact on the effects of TMS in the studied population. Therefore, better, well-developed TMS studies that test specific underlying neurobiological working mechanisms in schizophrenia are warranted. Moreover, schizophrenia is not a static, but rather a dynamic, disorder; therefore, TMS studies should focus more on patients with different stages of schizophrenia, i.e. patients experiencing their first episode of schizophrenia versus patients with chronic schizophrenia.

Second, within the studies, insufficient attention has been paid to the safety of using TMS on patients with schizophrenia. This is remarkable considering that a vivid discussion of the risks of using TMS to treat psychiatric patients is ongoing³. From the literature,
instance, human subjects, after having been treated with TMS, are known to suffer from minor complaints, such as headaches, pain due to burns caused by the scalp electrodes, local pain, etc.,[4,5] and major complaints, such as mood changes, seizures, induction of hypomania, etc.[4,5]. Obviously, in an extremely vulnerable population, such as patients suffering from schizophrenia, those side-effects might be more prominent and may lead to even more adverse events and difficulties in the patient’s life.

Third, as to the underlying neurobiology and possible treatment interventions of TMS in patients with schizophrenia, the clinical diagnostic issue of the heterogeneity of the disorder, which is a typical characteristic of schizophrenia, is not taken into account[6]. Although the symptoms may be common, schizophrenia may have many different causes that are influenced by genetic and environmental factors, resulting in a very heterogenic population of patients[7]. The answers to the questions of how informative the TMS findings that have been collected on schizophrenia so far[1] with respect to those subtypes of patient groups with schizophrenia are and what those findings mean at the individual patient level (e.g. with respect to gender differences, interactions with individual pharmacological treatments, etc.) remain unclear.

To conclude, the critical issues mentioned above are shown in Figure 1. If progress is to be made in understanding the underlying neurobiology of schizophrenia and in particular, if safe TMS-based treatments are to be developed for patients suffering from this disease, these issues need to be addressed in future, well-designed TMS studies. The results of such studies should more clearly expose the full potential of using TMS in the treatment of patients with schizophrenia.

**DECLARATIONS**

**Authors’ contributions**

Drafted the manuscript text, developed the intellectual ideas, managed the vivid discussions with the other members of the research group, made the suggested revisions, and approved the final version to be published: P. Bosch, M. van den Noort

Made both intellectual and textual suggestions for improvement, contributed to the vivid discussions with the other members of the research group and approved the final version to be published: S. Yeo, H. Staudte, P. Barisch

Made intellectual suggestions for improvement, contributed to the vivid discussions with the other members of the research group and approved the final version to be published: S. Lim

**Financial support and sponsorship**

None.

**Conflicts of interest**

There are no conflicts of interest.

**Patient consent**

Not applicable.

**Ethics approval**

Not applicable.

**REFERENCES**


